Intech Investment Management LLC raised its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 159.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,444 shares of the medical research company's stock after acquiring an additional 1,501 shares during the period. Intech Investment Management LLC's holdings in IQVIA were worth $480,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. GSA Capital Partners LLP bought a new stake in shares of IQVIA during the third quarter worth $230,000. Pathstone Holdings LLC raised its position in IQVIA by 4.8% during the 3rd quarter. Pathstone Holdings LLC now owns 14,492 shares of the medical research company's stock worth $3,434,000 after purchasing an additional 667 shares during the last quarter. Prospera Financial Services Inc acquired a new position in shares of IQVIA in the 3rd quarter valued at about $245,000. Avior Wealth Management LLC increased its position in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after buying an additional 87 shares in the last quarter. Finally, Advisors Asset Management Inc. boosted its holdings in IQVIA by 74.3% during the third quarter. Advisors Asset Management Inc. now owns 2,845 shares of the medical research company's stock worth $674,000 after purchasing an additional 1,213 shares during the last quarter. Institutional investors own 89.62% of the company's stock.
Analyst Ratings Changes
Several analysts have recently weighed in on IQV shares. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Barclays lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Truist Financial reiterated a "buy" rating and issued a $263.00 target price (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Finally, William Blair reissued an "outperform" rating on shares of IQVIA in a research note on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $249.05.
View Our Latest Analysis on IQV
IQVIA Stock Performance
Shares of NYSE IQV traded down $5.04 during mid-day trading on Tuesday, hitting $181.07. The stock had a trading volume of 1,566,007 shares, compared to its average volume of 1,241,421. The company has a 50 day moving average of $194.58 and a two-hundred day moving average of $207.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a market cap of $31.93 billion, a PE ratio of 24.14, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $253.84.
IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
